1. South Korea Stocks

  2. •

    Utilities

  3. •

    Renewable Utilities
HLB Life Science Co Ltd

HLB Life Science Co Ltd

067630.KS
HLB Life Science Co LtdKR flagKorea Exchange
11,250.00
KRW
-250.00
- -
HLB Life Science Co Ltd
067630.KS
(Korea Exchange)

Recent

price

11,250.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,098.07
2,334.47
496.6
1,057.03
1,151.04
722.43
738.36
1,869.5
1,606.62
1,158.25
438.18
508.37
979.38
897.35
293.65
375.48
422.2
Revenue per Share
106.79
-229.32
-460.86
-215.79
44.17
-450.57
-21.88
136.31
-285.2
-77.25
-266.34
-467.1
-533.76
-54.79
55
-819
-413.51
Basic EPS, GAAP
-291.39
553.72
348.22
151.88
311.36
-132.95
-62.47
-10.7
-338.8
-283.15
-89.73
-158.65
-407.1
-288.81
-532.91
-401.11
-356.25
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
649.91
169.83
-274.86
159.15
268.95
-86.28
-78.46
365.98
113.1
200.65
-172.7
13.21
77.37
566.28
697.04
-180.42
-244.08
Book Value per Share
1,171.69
865.41
386.46
581.73
255.62
657.46
410.55
890.82
1,576.7
2,418.45
1,004.35
1,746.73
1,422.34
1,606.35
3,172.51
2,018.92
1,989.53
Tangible Book Value per Share
19
18
18
19
32
38
57
57
64
98
209
105
102
109
112
122
122
Basic Weighted Avg Shares
40,518
40,953
8,998
19,956
36,560
27,323
42,234
106,445
102,476
114,019
91,797
53,494
99,591
97,990
32,771
45,752
51,512
Sales/Revenue/Turnover
10.85
-13.06
-51.96
-16.04
3.97
-35.48
-2.7
0.95
-7.59
-3.92
-8.73
-34.26
-20.03
-25.02
-60.93
-45.95
-42.33
Operating Margin (%)
87
59
318
556
537
714
348
319
346
1,902
2,255
2,484
5,223
7,696
5,901
5,247
6,518
Depreciation Expense
2,062
-4,023
-8,350
-4,074
1,403
-17,041
-1,251
7,761
-18,191
-7,605
-55,797
-49,152
-54,277
-5,983
6,138
-99,794
-50,452
Net Income, GAAP
27.51
- -
- -
- -
- -
- -
- -
0.93
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
5.09
-9.82
-92.8
-20.42
3.84
-62.37
-2.96
7.29
-17.75
-6.67
-60.78
-91.88
-54.5
-6.11
18.73
-218.12
-97.94
Profit Margin (%)
321
1,214
-4,624
6,041
1,890
17,485
18,239
37,900
190,448
183,822
163,464
143,286
133,991
11,586
101,745
-49,881
-58,409
Working Capital
15,641
19,551
12,879
6,896
4,342
2,156
17,635
8,719
80,074
10,575
11,014
3,953
137,021
51,834
82,722
56,330
55,930
LT Debt
23,264
15,234
7,041
11,034
13,441
25,895
27,685
52,826
206,114
334,425
287,744
246,612
236,067
231,213
398,825
297,742
293,981
Total Equity
7.38
- -
- -
- -
- -
- -
- -
1.82
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
8.76
- -
- -
- -
- -
- -
- -
36.51
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
17.94
-51.81
- -
- -
24.3
- -
- -
- -
-129.69
-56.4
- -
- -
-1,172.57
-17.17
8.79
- -
-488.5
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
97,952
104,027
108,136
LT Borrowings
56,249
54,473
53,917
LT Finance Leases
196
1,857
2,013
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
122
122
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
101,793
68,935
70,697
Cash, Cash Equivalents & STI
24,870
13,878
19,748
Accounts Receivable, Net
14,446
14,975
18,277
Inventories
5,670
6,791
5,860
Total Current Liabilities
108,889
118,815
129,106
Payables & Accruals
- -
- -
- -
ST Debt
97,952
104,027
108,136
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.27%
5.3%
-25.35%
Free Cash Flow
351.47%
36.74%
-17.82%
Net Income, GAAP
-259.07%
-403.78%
-1,725.88%
Sales/Revenue/Turnover
21.05%
3.18%
39.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
23,894
7,477
8,194
28,682
32,771
2025
9,439
11,769
13,596
10,948
45,752
2026
15,199
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,316.93
-1,334
591
- -
55
2025
-470
-213
-301
- -
-819
2026
-63.98
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
The Kansai Electric Power Company, Incorporated (KAEPF)
VIASPACE Inc. (VSPC)
Solarpack Corporacion Tecnologica, S.A. (SPK.MC)
Orrön Energy AB (publ) (ORRON.ST)
Phinergy Ltd. (PHNGF)
HD Renewable Energy Co., Ltd. (6873.TW)
Business
HLB Life Science Co Ltd operates across dual strategic pillars: the life science and energy sectors. Its biotechnology and healthcare division is dedicated to developing and manufacturing in vitro diagnostic medical solutions and specialty pharmaceutical products, including advancement in various anticancer therapies and other bio-development initiatives. The company also plays a role in the distribution of pharmaceuticals. Parallel to its medical endeavors, the energy services segment focuses on implementing energy-saving facilities, waste heat recovery solutions, and sophisticated cogeneration systems. This division is additionally involved in harnessing diverse renewable energy sources, such as solar power, for sustainable development.